IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Trial details
- Registry ID
- NCT05155254
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)NCT05155254 | IO Biotech | Phase 3 | Active not recruiting | 2025-05-30Actual |
| Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsNCT05280314 | IO Biotech | Phase 2 | Recruiting | 2025-04-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |